Comparative Pharmacology
Head-to-head clinical analysis: BINOSTO versus SKELID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINOSTO versus SKELID.
BINOSTO vs SKELID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
SKELID (tiludronate disodium) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity and recruitment.
70 mg orally once weekly
400 mg (2 tablets) orally once daily, taken on an empty stomach at least 2 hours before or after food, for 2 hours with 8 oz plain water; avoid other beverages, food, and medications for 2 hours post-dose.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis
Terminal elimination half-life: 10-12 hours (prolonged in renal impairment; no dose adjustment required for mild-moderate impairment but contraindicated in severe impairment [CrCl <30 mL/min])
Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible
Renal: 50-60% unchanged drug; biliary/fecal: <5%
Category C
Category C
Bisphosphonate
Bisphosphonate